Durvalumab: First Global Approval

@inproceedings{Syed2017DurvalumabFG,
  title={Durvalumab: First Global Approval},
  author={Yahiya Y. Syed},
  booktitle={Drugs},
  year={2017}
}
Intravenous durvalumab (Imfinzi™; AstraZeneca) is a fully human monoclonal antibody that blocks programmed cell death ligand-1 binding to its receptors (PD-1 and CD80), resulting in enhanced T-cell responses against cancer cells. The US FDA has granted durvalumab accelerated approval for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy, or within 12 months of neoadjuvant or… CONTINUE READING
9 Citations
23 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC) [abstract no. 5026 plus poster

  • F Karzai, RA Madan, H Owens
  • J Clin Oncol
  • 2017
1 Excerpt

FDA approval for complementary PD-L1 (SP263) biomarker test in urothelial carcinoma

  • Roche. Roche
  • [media release]
  • 2017
2 Excerpts

Phase 2 study to evaluate safety and efficacy of MEDI4736 (durvalumab [DUR]) in glioblastoma (GBM) patients: an update [abstract no. 2042 plus poster

  • DA Reardon, TJ Kaley, J Dietrich
  • J Clin Oncol
  • 2017
1 Excerpt

Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC) [abstract no. 4525 plus poster

  • NM Hahn, T Powles, C Massard
  • J Clin Oncol
  • 2017
2 Excerpts

Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD- L1 antibody: a phase 1, open-label study in advanced malig- nancies [abstract no. 1050PD

  • O Hamid, LQ Chow, RE Sanborn
  • Ann Oncol
  • 2016
2 Excerpts

Similar Papers

Loading similar papers…